Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
In spite of spectacular advances in the treatment of acute coronary syndromes in the past few years, they are still characterized by a high mortality which in real life is more than 10% at 6 months. This joint Symposium between the ESC and AHA provided an update on the most recent studies on the mechanisms responsible for acute coronary syndromes and on new potential targets for the anti-thrombotic and anti-inflammatory treatments.
Pullback during angio to generate Chemogram
Inflammation regulates the fragility of the fibrous cap, as well as the thrombogenic potential of the plaque.
Main features of inflammation associated with ACS:
Nonspecific anti-inflammatory drugs
Specific antagonists of key cytokines
Della Bona R. Curr Pharm Des 2011;17:4172-89
As noted in the diagram, some patients may benefit from a larger relative contribution of antiplatelet therapy while others may need more anticoagulant therapy. The relative needs in individual patients may also change as time progresses after their ACS event.
From bench to practice: pathogenesis and treatment of acute coronary syndromes
© 2017 European Society of Cardiology. All rights reserved